Form 8-K - Current report:
SEC Accession No. 0001104659-25-099356
Filing Date
2025-10-14
Accepted
2025-10-14 17:19:23
Documents
19
Period of Report
2025-10-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2528502d2_8k.htm   iXBRL 8-K 38235
2 EXHIBIT 4.1 tm2528502d2_ex4-1.htm EX-4.1 95011
3 EXHIBIT 4.2 tm2528502d2_ex4-2.htm EX-4.2 98604
4 EXHIBIT 5.1 tm2528502d2_ex5-1.htm EX-5.1 14295
5 EXHIBIT 10.1 tm2528502d2_ex10-1.htm EX-10.1 209557
6 EXHIBIT 10.2 tm2528502d2_ex10-2.htm EX-10.2 26619
7 EXHIBIT 99.1 tm2528502d2_ex99-1.htm EX-99.1 7896
11 GRAPHIC tm2528502d2_ex5-1img01.jpg GRAPHIC 4919
  Complete submission text file 0001104659-25-099356.txt   784592

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA anvs-20251010.xsd EX-101.SCH 3020
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20251010_lab.xml EX-101.LAB 34239
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20251010_pre.xml EX-101.PRE 22362
21 EXTRACTED XBRL INSTANCE DOCUMENT tm2528502d2_8k_htm.xml XML 3790
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 251392643
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)